NBIX - ニュ―ロクライン・バイオサイエンシズ (Neurocrine Biosciences Inc.)

NBIXのニュース

   Neurocrine Biosciences Dumpster-Dives To Accelerate Its International Business Development  2022/08/31 15:50:41 Seeking Alpha
Neurocrine is acquiring beaten-down Diurnal Group for $57M to accelerate its ex-U.S. business development. Find out what this means for investors in NBIX stock.
   NBIX stock on watch after deal to acquire Diurnal (NASDAQ:NBIX)  2022/08/30 11:32:08 Seeking Alpha
The shares of U.K.-based biotech Diurnal rose in London in the morning hours Tuesday after the company announced a deal to be acquired by San Diego, California-based Neurocrine…
   Neurocrine Is Seeing A Welcome Pick Up In Ingrezza, But Pipeline Catalysts Are Thin (NBIX)  2022/08/08 16:36:19 Seeking Alpha
Neurocrine saw a meaningful improvement in Ingrezza sales, with revenue growing 32% and beating sell-side expectations by 8%.
   Neurocrine stock rises as Q2 revenue soars 31% Y/Y, raises sales outlook for Ingrezza  2022/08/05 16:45:36 Seeking Alpha
Neurocrine Biosciences (NBIX) stock rose ~8% on Aug
   Neurocrine Biosciences Shares Jump After Raising Ingrezza Sales Guidance  2022/08/05 15:33:40 Benzinga
Tucked in its Q2 earning release , Neurocrine Biosciences Inc (NASDAQ: NBIX ) said that in August, the Phase 2a study of NBI-827104 in essential tremor did not meet specified endpoints. Based on the totality of data from the Phase 2a study, at this time, the company will not proceed further with the clinical development of NBI-827104 in essential tremors. The Full story available on Benzinga.com
   Neurocrine Is Seeing A Welcome Pick Up In Ingrezza, But Pipeline Catalysts Are Thin (NBIX)  2022/08/08 16:36:19 Seeking Alpha
Neurocrine saw a meaningful improvement in Ingrezza sales, with revenue growing 32% and beating sell-side expectations by 8%.
   Neurocrine stock rises as Q2 revenue soars 31% Y/Y, raises sales outlook for Ingrezza  2022/08/05 16:45:36 Seeking Alpha
Neurocrine Biosciences (NBIX) stock rose ~8% on Aug
   Neurocrine Biosciences Shares Jump After Raising Ingrezza Sales Guidance  2022/08/05 15:33:40 Benzinga
Tucked in its Q2 earning release , Neurocrine Biosciences Inc (NASDAQ: NBIX ) said that in August, the Phase 2a study of NBI-827104 in essential tremor did not meet specified endpoints. Based on the totality of data from the Phase 2a study, at this time, the company will not proceed further with the clinical development of NBI-827104 in essential tremors. The Full story available on Benzinga.com
   Sosei to get $30M from Neurocrine as schizophrenia drug gets FDA nod to enter trial  2022/08/05 09:21:41 Seeking Alpha
Sosei Group (SOLTF) is getting $30M as milestone payment as Neurocrine Biosciences (NBIX) is going to start a phase 2 trial of NBI-1117568 to treat…
   Neurocrine Biosciences (NBIX) Q2 2022 Earnings Call Transcript  2022/08/05 08:30:22 The Motley Fool
NBIX earnings call for the period ending June 30, 2022.
   Neurocrine Biosciences Inc. (NASDAQ: NBIX) Has Outstanding Potential  2022/06/25 14:00:00 Stocks Register
Neurocrine Biosciences Inc. (NASDAQ:NBIX) shares, rose in value on Friday, 06/24/22, with the stock price up by 0.86% to the previous day’s close as strong demand from buyers drove the stock to $98.24. Actively observing the price movement in the last trading, the stock closed the session at $97.40, falling within a range of $95.81 … Neurocrine Biosciences Inc. (NASDAQ: NBIX) Has Outstanding Potential Read More »
   Neurocrine Biosciences to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference  2022/06/08 20:01:00 Neurocrine Biosciences
SAN DIEGO , June 8, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 43 rd Annual Global Healthcare Conference at 10:40 a.m. Pacific Time ( 1:40 p.m. Eastern Time ) on Wednesday, June 15, 2022 in Rancho Palos Verdes, CA.
   Neurocrine Biosciences to repurchase $179.4M of 2.25% Convertible Senior Notes due 2024  2022/05/25 10:05:11 Seeking Alpha
   Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms at American Psychiatric Association Annual Meeting 2022  2022/05/23 12:30:00 Neurocrine Biosciences
SAN DIEGO , May 23, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data on the use of INGREZZA ® (valbenazine) capsules for the treatment of tardive dyskinesia (TD) at the American Psychiatric Association (APA) Annual Meeting being held in
   Parkinson''s Disease (PD) Drugs market - 37% of Growth to Originate from Europe | Evolving Opportunities with AbbVie Inc. & Amneal Pharmaceuticals Inc. | Technavio  2022/05/18 06:30:00 Benzinga
NEW YORK , May 18, 2022 /PRNewswire/ -- The Parkinson''s disease (PD) drugs market size is expected to grow by USD 1.57 billion from 2019 to 2024 at a CAGR of 6% as per the latest market report by Technavio. 37% of the market''s growth will originate from Europe during the forecast period. Germany , Italy , the UK, and Spain are the key markets for Parkinson''s disease (PD) drugs in Europe . Market growth in this region will be faster than the market''s growth in the Asian and North American regions. The strong prevalence of PD and the easy availability of multiple approved drugs will facilitate the Parkinson''s disease (PD) drug market growth in Europe over the forecast period. For more insights on the market share of various regions - Download a sample report in MINUTES Read the 120-page report with TOC on "Parkinson''s Disease (PD) Drugs Market Analysis Report by D rug class (DA and levodopa-carbidopa, MAO inhibitors, AChE inhibitors, glutamate inhibitors, and others) and Geography ( Europe , North America , Asia , and ROW), and the Segment Forecasts,2020-2024".

calendar